Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 11

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 11
---
| Sharmila Dissanaike, M.D., FACS, FCCM |     |  50 |     | Director                             |     |           2021 |
| Craig Johnson                         |     |  63 |     | Director                             |     |           2014 |
| Michael Kaseta                        |     |  49 |     | Director                             |     |           2024 |
| Adam Morgan                           |     |  46 |     | Chairman of the Board                |     |           2023 |
| Christian Waage                       |     |  58 |     | Director                             |     |           2016 |

Susan Rodriguez is not standing for re-election at the Annual Meeting. She currently serves on the Compensation and Nominating and Corporate Governance Committees of the Board. Craig Collard has served as a director of Heron since February 2023 and as Chief Executive Officer since April 2023. Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., “ Veloxis ”) before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company (“ Cornerstone ”), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. (“ Chiesi ”) in 2014. Mr. Collard also served as Cornerstone’s Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from 2004 to 2008. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. Mr. Collard has served on the board of directors of TerrAscend Corp. (TSX: TSND), a North American cannabis operator based in Mississauga, Canada ("TerrAscend"), since December 2018. Mr. Coll